Suppr超能文献

恶性疟原虫二氢叶酸还原酶对乙胺嘧啶和氯环胍高度耐药,但对WR99210不耐药的新型等位基因。

Novel alleles of the Plasmodium falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210.

作者信息

Hankins E G, Warhurst D C, Sibley C H

机构信息

Department of Genetics, University of Washington, Seattle, WA 98195-7360, USA.

出版信息

Mol Biochem Parasitol. 2001 Sep 28;117(1):91-102. doi: 10.1016/s0166-6851(01)00335-8.

Abstract

We have expressed dhfr alleles of Plasmodium falciparum in the budding yeast, Saccharomyces cerevisiae, and used this yeast model to identify single amino acid substitutions that confer high level pyrimethamine resistance on the background of the triple mutant dhfr (I51+R59+N108). Mutations in three clusters were identified: codons 50-57, 187-193, and 213-214. Several mutations previously identified in field samples were also isolated, including codons 50 and 164. The I164L mutation is of particular interest, because the quadruple mutant genotype (N51I+C59R+S108N+I164L) encodes an enzyme that is no longer inhibited by pyrimethamine, rendering sulfadoxine/pyrimethamine (SP; Fansidar) clinically ineffective. Thirty-six novel alleles were tested to determine their sensitivity to chlorcycloguanil and WR99210, two DHFR inhibitors that are in clinical and pre-clinical development, respectively. Chlorcycloguanil is effective against parasites that carry the triple mutant allele, but in vitro analysis has suggested that chlorcycloguanil will be clinically ineffective against parasites that carry the quadruple mutant allele of dhfr. In our screen, 23 of 36 novel strains were as resistant to chlorcycloguanil as the quadruple mutant, and one strain was 10-fold more resistant. WR99210 is still effective in the nM range against parasites that carry the quadruple mutant allele. In the preliminary screen, 31 of 36 novel alleles were as sensitive to WR99210 as the quadruple mutant. Detailed analysis of the remaining five showed that four of the five had IC(50) values in the same range as the quadruple mutant, and one, N51I+C59R+S108N+E192G, had an IC(50) value about fivefold higher. This result suggests that WR99210 and related compounds will be clinically effective against quadruple mutants currently found in Southeast Asia and South America and against most novel alleles that could be selected on the background of the triple mutant genotype now prevalent in East Africa.

摘要

我们已在出芽酵母酿酒酵母中表达了恶性疟原虫的二氢叶酸还原酶(dhfr)等位基因,并利用该酵母模型确定了在三重突变dhfr(I51 + R59 + N108)背景下赋予高水平乙胺嘧啶抗性的单氨基酸取代。鉴定出三个簇中的突变:密码子50 - 57、187 - 193和213 - 214。还分离出了先前在野外样本中鉴定出的几种突变,包括密码子50和164。I164L突变特别令人关注,因为四重突变基因型(N51I + C59R + S108N + I164L)编码的一种酶不再受乙胺嘧啶抑制,使得磺胺多辛/乙胺嘧啶(SP;Fansidar)在临床上无效。测试了36个新的等位基因,以确定它们对氯环胍和WR99210的敏感性,这两种二氢叶酸还原酶抑制剂分别处于临床和临床前开发阶段。氯环胍对携带三重突变等位基因的寄生虫有效,但体外分析表明氯环胍对携带dhfr四重突变等位基因的寄生虫在临床上无效。在我们的筛选中,36个新菌株中有23个对氯环胍的抗性与四重突变体相同,有一个菌株的抗性高10倍。WR99210在纳摩尔范围内对携带四重突变等位基因的寄生虫仍然有效。在初步筛选中,36个新等位基因中有31个对WR99210的敏感性与四重突变体相同。对其余五个的详细分析表明,五个中有四个的半数抑制浓度(IC50)值与四重突变体在同一范围内,还有一个,即N51I + C59R + S108N + E192G,其IC50值大约高五倍。这一结果表明,WR99210及相关化合物对目前在东南亚和南美洲发现的四重突变体以及对在东非目前普遍存在的三重突变基因型背景下可能选择出的大多数新等位基因在临床上将是有效的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验